InvestSMART

AdAlta Limited (ASX:1AD)

ALERT: Price-sensitive ASX Announcement for 1AD
Current share price for 1AD : $0.004 0 (0%)+
Announcement
Release
5 Aug 2026 8:26AM
Price at Release
$0.004
Full Release
download
Summary
AdAlta Limited (ASX:1AD) reported a significant milestone in the ongoing Investigator Initiated Trial (IIT) of its lead CAR-T cell therapy, EW-001, for treating mesothelioma. The therapy has exhibited a promising 2-year survival milestone with the first patient achieving complete tumor clearance remaining cancer-free two years post-treatment, a rare outcome in advanced mesothelioma. A second patient has survived 12 months following complete response. The study shows a 20% complete response rate among patients treated with higher doses of EW-001. These results underscore the potential durability and effectiveness of EW-001 against mesothelioma, a rare but fatal cancer linked to asbestos exposure. AdAlta plans further follow-up to strengthen clinical evidence and aims to transition EW-001 manufacturing to Australia while preparing for a pre-IND meeting with the US FDA.
Key Points
  • AdAlta Limited reports significant milestone for EW-001 in mesothelioma treatment.
  • First complete responder cancer-free for two years post-treatment.
  • Second complete responder survives 12 months post-treatment.
  • 20% Complete Response rate achieved among higher dose group.
  • Durability of response seen in a rare and aggressive cancer type.
  • Plans to shift manufacturing to Australia and engage with US FDA.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.